SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.
about
P62: An emerging oncotarget for osteolytic metastasisChoosing the right cell line for renal cell cancer researchp62/SQSTM1 functions as a signaling hub and an autophagy adaptorDevelopment of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolutionp62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver CancerVHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2.RNA-Seq and ChIP-Seq reveal SQSTM1/p62 as a key mediator of JunB suppression of NF-κB-dependent inflammationMitophagy and cancer.The role for autophagy in cancer.High Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer.Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy.Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel autophagy regulator by high content shRNA screening.Bixin protects mice against ventilation-induced lung injury in an NRF2-dependent mannermiR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA.Regulation of glucose metabolism by p62/SQSTM1 through HIF1αMechanisms of Selective Autophagy in Normal Physiology and CancerAbsence of the Autophagy Adaptor SQSTM1/p62 Causes Childhood-Onset Neurodegeneration with Ataxia, Dystonia, and Gaze Palsy.p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA.VPS34 stimulation of p62 phosphorylation for cancer progression.p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer.Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.Autophagy-from molecular mechanisms to clinical relevance.Autophagy in the liver: functions in health and disease.Expanding perspectives on the significance of mitophagy in cancer.The KEAP1-NRF2 System in Cancer.p62 Regulates the Proliferation of Molecular Apocrine Breast Cancer CellsA novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization.Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy.Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposureSqstm1-GFP knock-in mice reveal dynamic actions of Sqstm1 during autophagy and under stress conditions in living cells.p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells.The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma.p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis.The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells.p62/SQSTM1 interacts with vimentin to enhance breast cancer metastasis.HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.MicroRNA-17-5p contributes to osteoarthritis progression by binding p62/SQSTM1.Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.Autophagy, Metabolism, and Cancer.
P2860
Q26753091-857ADE45-D805-4ABC-8DB2-5A108720F04EQ28073283-08600EE4-BFA8-455B-9D5D-1696018D3F1CQ28081418-B4F683B1-3181-405A-9BFF-348FF501BADDQ28655705-F3F8466B-4784-4D4B-9E96-62CFACE864A3Q29144909-36FFEE43-D520-4533-B9D5-674961BD7CF8Q33826897-852D7449-CD66-4E87-867A-169726B425D2Q35196307-3CB1E77F-A322-454C-961A-0A93C95B7CDAQ35215652-93C39485-60B5-4036-B2AF-770CEEF65058Q35242506-3ABE73BC-E1FF-4A85-AF79-5590E83E856EQ35288939-BF3FCB9E-1103-460D-838B-FCBE7C4D6F6DQ35626579-12358982-D18A-45A8-8A27-FFAD98949131Q36069096-DB2C197F-8CF4-41F2-B2BA-36F1C7D919FBQ36427836-28197BB5-DA35-4CA7-AA85-787D87F557D8Q36555180-05C01DD7-233C-436D-94DA-4578B0D53F4AQ36597622-64026CC0-E3C4-46E8-8E9E-8CA356FEEB1BQ36840116-3D16A022-522F-4B7A-A1D5-4B078A3E3813Q37230703-F4FBC2C8-D3AF-442C-9B4B-EDEF7FACE017Q37609205-3D208870-0D24-4E8F-9A4C-8CDE092E7D93Q38605920-3F2F0131-EBFE-48AB-ADBF-413AFB530A3FQ38893853-47A2C6DE-ADA3-498A-A559-18B6C2A125FEQ38977381-4297B850-73FC-4B9A-B76C-6155B8C5BFE7Q39037205-F8D55FFA-B093-473D-85D6-23A924EA3C04Q39067616-EABB9D19-9AC6-4624-9B10-4B79AE776FF0Q39267828-7629B855-8ADD-4C2B-9D37-C01CAD4B36EDQ39317112-9A4B7068-6B62-4920-B7BF-3C28CA6F23C7Q41014521-0F435D7A-0EAC-4919-9B61-9D64E44686D5Q41187419-970FFCD9-7F97-424B-974F-DA4FFF9C7541Q41678966-77DC8A08-AB58-416B-90D2-BFA23D8EEB8BQ41779657-22EBC18C-0578-4E66-95C9-D8435193D8F9Q41931500-ED4CBF92-E5A4-47A2-AAC1-3B491E3FD590Q42173389-0A0E3BA6-CC4C-4C95-B82B-FEAA14C33BA4Q42716243-2A7C5AA3-92A3-4C90-904A-1185F51F8B90Q45833979-D05A2962-E24F-4DB6-92A7-644617AFC759Q45946958-D86142CD-128B-4B27-885A-A3FAB6AED161Q46334875-741A5D98-9BCA-4A1C-853A-A8D69B4B85F8Q47715195-2FEF1D28-929F-4A8F-BBEB-D6B1A37FF307Q48136694-FBE0BAE9-F589-4510-A2B9-AA045DF73F17Q49478023-DB118B4F-B291-4A6A-8D34-84B178581129Q52321041-18A86EDF-8FEE-44DB-A1C7-06EB9F104193Q53210815-DB4AC7E1-DF23-45CE-9BED-A8A64889B8A6
P2860
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.
@en
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.
@nl
type
label
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.
@en
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.
@nl
prefLabel
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.
@en
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.
@nl
P2093
P2860
P50
P1433
P1476
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.
@en
P2093
A Ari Hakimi
Barbara Tabak
Chris Sander
Chuan Shen
David E Root
Eijiro Nakamura
Ella Liberzon
Glenn S Cowley
James J Hsieh
Kiyohiro Ando
P2860
P304
P356
10.1016/J.CCR.2013.10.025
P50
P577
2013-12-01T00:00:00Z